Log in

Relevant bibliographies by topics / Uveitis

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Uveitis'

Author: Grafiati

Published: 4 June 2021

Last updated: 4 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Uveitis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Uveitis"

1

Verma, Ashutosh, S. R. Rathinam, C. Gowri Priya, V. R. Muthukkaruppan, Brian Stevenson, and John F. Timoney. "LruA and LruB Antibodies in Sera of Humans with Leptospiral Uveitis." Clinical and Vaccine Immunology 15, no. 6 (April 9, 2008): 1019–23. http://dx.doi.org/10.1128/cvi.00203-07.

Full text

Abstract:

ABSTRACT Uveitis can be a serious complication of leptospirosis. Previous studies indicated that the leptospiral lipoproteins LruA and LruB are expressed in the eyes of uveitic horses and that antibodies directed against those proteins show in vitro cross-reactivity with components of equine lens, ciliary body, and/or retina. We now demonstrate that sera from a significant proportion of humans who have leptospiral uveitis also contain antibodies against LruA and LruB. Different categories of nonleptospiral uveitis and autoimmune uveitis were also screened; patients diagnosed with Fuchs uveitis or Behçet's syndrome produced antibodies that cross-reacted with LruA and LruB, suggesting similarities of the autoimmune responses in those diseases with those of leptospiral uveitis.

APA, Harvard, Vancouver, ISO, and other styles

2

Lorenz, Lea, Barbara Amann, Sieglinde Hirmer, Roxane L. Degroote, Stefanie M. Hauck, and Cornelia A. Deeg. "NEU1 is more abundant in uveitic retina with concomitant desialylation of retinal cells." Glycobiology 31, no. 7 (February 23, 2021): 873–83. http://dx.doi.org/10.1093/glycob/cwab014.

Full text

Abstract:

Abstract Desialylation of cell surface glycoproteins carried out by sialidases affects various immunological processes. However, the role of neuraminidase 1 (NEU1), one of the four mammalian sialidases, in inflammation and autoimmune disease is not completely unraveled to date. In this study, we analyzed the retinal expression of NEU1 in equine recurrent uveitis (ERU), a spontaneous animal model for autoimmune uveitis. Mass spectrometry revealed significantly higher abundance of NEU1 in retinal Müller glial cells (RMG) of ERU-diseased horses compared to healthy controls. Immunohistochemistry uncovered NEU1 expression along the whole Müller cell body in healthy and uveitic states and confirmed higher abundance in inflamed retina. Müller glial cells are the principal macroglial cells of the retina and play a crucial role in uveitis pathogenesis. To determine whether higher expression levels of NEU1 in uveitic RMG correlate with the desialylation of retinal cells, we performed lectin-binding assays with sialic acid-specific lectins. Through these experiments, we could demonstrate a profound loss of both α2-3- and α2-6-linked terminal sialic acids in uveitis. Hence, we hypothesize that the higher abundance of NEU1 in uveitic RMG plays an important role in the pathogenesis of uveitis by desialylation of retinal cells. As RMG become activated in the course of uveitis and actively promote inflammation, we propose that NEU1 might represent a novel activation marker for inflammatory RMG. Our data provide novel insights in the expression and implication of NEU1 in inflammation and autoimmune disease.

APA, Harvard, Vancouver, ISO, and other styles

3

Smeller, Lilla, Viktória Sümegi, Edit Tóth-Molnár, and Nicolette Sohár. "A biológiai terápia helye a gyermekkori uveitis ellátásában." Orvosi Hetilap 163, no. 35 (August 28, 2022): 1402–8. http://dx.doi.org/10.1556/650.2022.32578.

Full text

Abstract:

Bevezetés: A gyermekkori uveitisek kezelésében 2016 óta van lehetőség biológiai terápia alkalmazására. Szemészeti indikáció esetén adalimumabbal indítható terápia, mely egy tumornekrózisfaktor-ellenes monoklonális antitest. Célkitűzés: Klinikánk uveitisambulanciáján a gyermekkori uveitis miatt kezelt betegek adatainak retrospektív feldolgozása alapján a nem fertőzéses eredetű uveitis esetén alkalmazott adalimumabkezelésről szerzett tapasztalataink összefoglalása. Betegek és módszerek: Restrospektív módon elemeztük a Szegedi Tudományegyetem Szemészeti Klinikáján 2017. 01. 01. és 2021. 05. 31. között uveitis miatt gondozott gyermekek adatait. Eredmények: 2017 és 2021 között 46 uveitises gyermeket vizsgáltunk klinikánkon. A 23 lány és 23 fiúgyermek átlagéletkora 11 év volt. Közülük 21 gyermek szenvedett juvenilis idiopathiás arthritisben, 14 gyermeknél igazolódott infekció, 3 gyermeknél hematológiai betegség okozta az elváltozást, 8 gyermeknél idiopathiás eredetű volt a gyulladás. Krónikus, súlyos uveitis miatt 11 gyermeknél indítottunk biológiai terápiát az Európai Gyógyszerügynökség engedélye alapján. 3 fiúgyermek és 8 lánygyermek részesült adalimumabkezelésben, átlagéletkoruk 10 év volt. 6 gyermeknél anterior, 5 gyermeknél panuveitis indikálta a kezelést. Az adalimumab alkalmazási leirata szerint 2 évnél idősebb gyermekeknél a krónikus, nem fertőzéses eredetű szemgyulladás kezelésére alkalmazható, amikor a gyulladás a szem elülső részét érinti. Panuveitises betegeink esetén gyermekreumatológus segítségét kértük a biológiai terápia engedélyezéséhez. Következtetés: A gyermekkori uveitisek és azok terápiájának jelentősége kiemelkedő. A szemészeti kezelés célja a gyermekek látásélességének megőrzése és a szemészeti szövődmények megelőzése mellett a betegek megfelelő életminőségének biztosítása. Kiemelkedő fontosságú a korai diagnózis, a megfelelő terápia, a rendszeres kontrollvizsgálat. Az adalimumab hatékonyságát mutatja, hogy a kezelt gyermekek jelentős százalékánál sikerült a teljes látásélességet elérni, valamint a kezelés mellett újabb szemészeti szövődmény nem alakult ki. Orv Hetil. 2022; 163(35): 1402–1408.

APA, Harvard, Vancouver, ISO, and other styles

4

Al-Ani, Haya H., Joanne L. Sims, Oren Tomkins-Netzer, Susan Lightman, and Rachael L. Niederer. "Vision loss in anterior uveitis." British Journal of Ophthalmology 104, no. 12 (April 3, 2020): 1652–57. http://dx.doi.org/10.1136/bjophthalmol-2019-315551.

Full text

Abstract:

AimsTo evaluate the long-term risk of permanent vision loss in subjects with anterior uveitis.MethodsRetrospective study of subjects attending uveitis clinic at Auckland District Health Board and Moorfields Eye Hospital between 2008 and 2018. Main outcome measures were: best corrected visual acuity (BCVA); moderate vision loss (MVL ≤20/50); and severe vision loss (SVL ≤20/200).Results2526 eyes of 1814 subjects were included with a mean follow-up of 6.8 years (17 235.4 eye-years of follow-up). MVL occurred in 240 eyes (9.5%) during the follow-up period, of which 97 (3.8%) had permanent MVL due to uveitis. The incidence of permanent MVL due to uveitis was 0.006 per eye-year with a cumulative risk at 10 years of 6.6% (5.2%–8.4%). The most common cause of permanent MVL due to uveitis was uveitic glaucoma (31.3%), followed by cystoid macular oedema (27.1%) and corneal scar (21.9%). SVL occurred in 80 eyes (3.2%) during the follow-up period, of which 39 (1.5%) had permanent SVL due to uveitis. The incidence of permanent SVL due to uveitis was 0.002 per eye-year with a cumulative risk at 10 years of 2.6% (1.8%–3.7%). Multivariate analysis showed older age at presentation, chronic anterior uveitis (CAU), infectious aetiology and poor presenting BCVA were all risk factors for permanent MVL due to uveitis.ConclusionsAlthough vision loss is an uncommon complication in anterior uveitis, the risk is greatest in those with CAU, infectious aetiology and poor presenting BCVA. Uveitic glaucoma is the most common cause of vision loss.

APA, Harvard, Vancouver, ISO, and other styles

5

Juhong, Jakkrit, Krit Pongpirul, Somtaporn Ueathaweephol, Thanapong Somkijrungroj, and Wijak Kongwattananon. "The patterns of uveitis and the factors affecting visual outcome from Chulalongkorn University Uveitis Cohort (CU2C): A 5-year longitudinal study protocol." PLOS ONE 17, no. 10 (October 6, 2022): e0275666. http://dx.doi.org/10.1371/journal.pone.0275666.

Full text

Abstract:

Background In Thailand, several novel laboratory investigations are recently available to help differentiate the uveitic etiologies. The update on uveitis epidemiological data in Thailand is necessary to better understand the disease burden and provide guidance on management. The current study aims to describe the prevalence and identify factors associated with poor visual outcomes of uveitis patients at a tertiary center in Thailand. Methods A 5-year-prospective study of uveitis cases presented at a tertiary referral center in the central region of Thailand is conducted.

APA, Harvard, Vancouver, ISO, and other styles

6

Al-Dhibi, Hassan, Issam H. Hamade, Ali Al-Halafi, Maan Barry, Charbel Bou Chacra, Vishali Gupta, and Khalid F. Tabbara. "The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema." Journal of Ophthalmology 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/729465.

Full text

Abstract:

Background/Aims.To assess the effect of intravitreal bevacizumab injection (IVBI) for the treatment of macular edema due to infectious and noninfectious uveitides.Design.Retrospective interventional case series.Methods.A chart review was performed on all the patients who were diagnosed with uveitic macular edema (UME) and received 1.25 mg of IVBI at two referral centers in Riyadh, Saudi Arabia. All included patients had their visual acuity and macular thickness analyzed at baseline and at 1 and 3 months following IVBI and any sign of reactivation was noted.Results.The mean age of patients was41±16years with a mean followup of4±1months. Ten patients had idiopathic intermediate uveitis, 9 patients had Behcet’s disease, 10 had idiopathic panuveitis, and twelve patients had presumed ocular tuberculosis uveitis. Following IVBI, the mean LogMAR visual acuity improved from0.8±0.8at baseline to0.4±0.5at 1 month and0.3±0.5at 3 months (P<0.002, at 3 months). The mean macular thickness was430±132 μm at baseline. Following IVBI macular thickness improved to286±93 μm at 1 month and to265±88 μm at 3 months of followup (P<0.001, at 3 months).Conclusion.Bevacizumab was effective in the management of UME associated with both infectious and noninfectious uveitides. Intravitreal bevacizumab induced remission of UME with infectious uveitis and had no immunosuppressive effect against infectious agents.

APA, Harvard, Vancouver, ISO, and other styles

7

Iannetti, Ludovico, Paolo Tortorella, Enzo D’Ambrosio, Rossela Spena, Roberta Zito, and Magda Gharbiya. "Epiretinal Membranes in Patients with Uveitis: Morphological and Functional Analysis with Spectral Domain Optical Coherence Tomography." BioMed Research International 2013 (2013): 1–7. http://dx.doi.org/10.1155/2013/284821.

Full text

Abstract:

Purpose. To correlate the uveitic epiretinal membrane (ERM) features using spectral-domain optical coherence tomography (SD-OCT) with visual acuity (VA).Methods. Forty-one eyes of 32 patients were included in this retrospective study. SD-OCT was performed in all patients and data were collected at the time of ERM diagnosis and at the final visit. Both best corrected visual acuity (BCVA) and ERM thickness were correlated with the morphological and clinical features.Results. Final BCVA was positively correlated with male sex and the focal pattern of ERM attachment and negatively correlated with IS/OS photoreceptor junction disruption . BVCA change showed a positive correlation with the age of ERM onset but a negative correlation with IS/OS photoreceptor disruption at the ERM diagnosis and the increase of central subfield thickness (CST) . Final ERM thickness correlated with the duration of uveitis and the duration of ERM . During the follow-up, ERM thickening correlated with male sex , posterior uveitis , uveitis duration , and broad attachment pattern .Conclusions. In the uveitic ERM, VA negatively correlates with IS/OS photoreceptor junction disruption and the increase of CST. ERM thickness is influenced by longer duration of both uveitis and ERM.

APA, Harvard, Vancouver, ISO, and other styles

8

Thorne, J., D. Jabs, R. Belfort, A. Dick, S. Gangaputra, R. Nussenblatt, A. Okada, J. Rosenbaum, and B. Trusko. "The Standardization of Uveitis Nomenclature (SUN) Project." Methods of Information in Medicine 52, no. 03 (2013): 259–65. http://dx.doi.org/10.3414/me12-01-0063.

Full text

Abstract:

SummaryBackground: Given the recent increased focus on evidence-based medicine, it is critical that diseases and syndromes have accurate and complete descriptions, including standardized and widely accepted terminologies. Standardizing these descriptions and terminologies is necessary to develop tools such as computerized data entry forms and classification criteria. This need is especially true for diseases that are relatively uncommon, such as uveitis.Objectives: To develop a standardized and internationally accepted terminology for the field of uveitis.Methods: The Standardization of Uveitis Nomenclature (SUN) Working Group (WG) is an international group of 79 uveitis experts from 18 countries and 62 clinical centers. Initial terminology was developed utilizing a “modified” green field approach, which was enhanced through web-based surveys and teleconferences via a “modified” Delphi technique. Terms were mapped provisionally into ontologic dimensions for each syndrome. The Working Group then met and utilized nominal group techniques as a formalized method of finalizing the mappings.Results: Mapping of terms into dimensions to describe 28 major uveitic diseases was confirmed using nominal group techniques (achieving super-majority consensus) for each of the diseases at a meeting of the entire WG.Conclusions: The SUN WG utilized an informatics-based approach to develop a stand ardized and internationally accepted terminology for the uveitides.

APA, Harvard, Vancouver, ISO, and other styles

9

Conrady, Christopher D., and Steven Yeh. "A Review of Ocular Drug Delivery Platforms and Drugs for Infectious and Noninfectious Uveitis: The Past, Present, and Future." Pharmaceutics 13, no. 8 (August 8, 2021): 1224. http://dx.doi.org/10.3390/pharmaceutics13081224.

Full text

Abstract:

Uveitis refers to a broad group of inflammatory disorders of the eye that often require medical and surgical management to improve or stabilize vision and prevent vision-threatening pathological changes to the eye. Drug delivery to the eye to combat inflammation and subsequent complications from uveitic conditions is complex as there are multiple barriers to absorption limiting availability of the needed drug in the affected tissues. As such, there has been substantial interest in developing new drugs and drug delivery platforms to help reduce intraocular inflammation and its complications. In this review, we discuss the challenges of drug delivery, novel technologies recently approved for uveitis patient care and promising drug delivery platforms for uveitis and sequelae of ocular inflammation.

APA, Harvard, Vancouver, ISO, and other styles

10

Du, Lin, Yolanda Wong Ying Yip, Him Kwan Ng, Bo Man Ho, Jing-Na He, Sun On Chan, Chi Pui Pang, and Wai Kit Chu. "Ruxolitinib Alleviates Uveitis Caused by Salmonella typhimurium Endotoxin." Microorganisms 9, no. 7 (July 11, 2021): 1481. http://dx.doi.org/10.3390/microorganisms9071481.

Full text

Abstract:

Uveitis is characterized by inflammatory lesions of intraocular structures. It is one of the important manifestations in patients with Reiter’s syndrome, an inflammatory arthritis, which is caused by enteric infection with bacteria, including Salmonella typhimurium. Corticosteroids remain the most frequently used therapies against uveitis associating with inflammatory arthritis. However, the long-term administration of steroids results in many side effects, and some uveitis patients do not respond to steroid treatment. Non-steroidal treatments are needed for uveitis patients. Our previous study found that Janus kinase (JAK) 1/2 inhibitor, ruxolitinib could suppress the expression of proinflammatory mediators in the ciliary body and iris. However, the impacts of ruxolitinib on ophthalmic features in uveitic eyes are still unknown. In this study, Salmonella typhimurium endotoxin-induced uveitis (EIU) was induced in Sprague Dawley rats by the injection of lipopolysaccharide (LPS). Compared with LPS-induced rats treated with water, ruxolitinib significantly attenuated the clinical manifestations, infiltrating cells and protein exudation in the aqueous humor, and retina–choroid thickening. Amplitudes of b-wave in both scotopic and photopic electroretinogram (ERG), and the amplitude of a-wave in scotopic ERG in EIU animals were alleviated by ruxolitinib. Collectively, we propose ruxolitinib could attenuate endotoxin-induced uveitis and rescue visual functions in rats by inhibiting the JAK2-STAT3 pathway.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Uveitis"

1

Santos, Hercos Benigno Vicente. "Ecografía en Uveitis." Doctoral thesis, Universitat Autònoma de Barcelona, 2001. http://hdl.handle.net/10803/4242.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hofmaier, Florian. "Equine rezidivierende Uveitis." Diss., lmu, 2010. http://nbn-resolving.de/urn:nbn:de:bvb:19-118798.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Puchta, Joachim. "Experimentelle Melanin-induzierte Uveitis." [S.l.] : [s.n.], 2001. http://deposit.ddb.de/cgi-bin/dokserv?idn=963814621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Garip-Kuebler, Aylin. "Rare anterior uveitis entities." Diss., Ludwig-Maximilians-Universität München, 2014. http://nbn-resolving.de/urn:nbn:de:bvb:19-167080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Puchta, Joachim. "Experimentelle Melanin-induzierte Uveitis." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2002. http://dx.doi.org/10.18452/14690.

Full text

Abstract:

Experimentelle Melanin-induzierte Uveitis (EMIU): Modulation der Leukozyten-Endothelzell-Interaktion durch Makrophagendepletion - intravitalmikroskopische Analysen. Einleitung: Die Experimentelle Melanininduzierte Uveitis (EMIU) dient als Modell für eine autoimmune Iridozyklitis und Choroiditis. Die frühe Entzündungsreaktion ist durch eine gesteigerte Leukozyten-Endothel-Interaktion gekennzeichnet. Um die Rolle von Makrophagen bei der Induktion der EMIU zu untersuchen, analysierten wir Veränderungen der Leukozyten-Endothel-Interaktionen in Irisvenolen anästhesierter Ratten nach Makrophagendepletion mit liposomalem Clodronat. Methoden: Die EMIU wurde durch intraperitoneale Injektion einer Emulsion aus 250 µg bovinen Melanosomen in komplettem Freund Adjuvant und Pertussistoxin bei Lewis Ratten induziert. Die Tiere wurden mit 2 ml Clodronat-Liposomen (Clodronat-lip) an den Tagen 2; 1; 4; 6 beziehungsweise 8 nach Immunisierung behandelt. Kontrolltiere erhielten anstelle von Clodronat-lip Leerliposomen (Kontrolle). Für die Intravitalfluoreszenzmikroskopie wurden Leukozyten intravasal mit Rhodamin 6G gefärbt. Anschließend wurden die postkapillären Irisvenolen am 4.; 6.; 8. und 10. Tag untersucht, um die Zahl der rollenden und fest am Endothel adhärenten Leukozyten zu quantifizieren. Weitere Parameter wie Zellzahl und Proteingehalt des Kammerwassers, TNF-alpha und IFN-gamma im Plasma und das Differentialblutbild wurden zur Charakterisierung der Entzündungsreaktion herangezogen. Ergebnisse: Bei makrophagendepletierten Tieren konnten spaltlampenmikroskopisch keine entzündlichen Veränderungen des Vorderabschnittes beobachtet werden. Der prozentuale Anteil rollender Leukozyten war am 8. Tag mit 2 +/- 1.1 vs. 15.2 +/- 1.6; 5.2 +/- 0.5% (Clodronat-lip vs. EMIU; Kontrolle, Mittelwert +/- MSF, ANOVA, p

APA, Harvard, Vancouver, ISO, and other styles

6

Dua, Harminder Singh. "Immunomodulation of experimental autoimmune uveitis." Thesis, University of Aberdeen, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.317710.

Full text

Abstract:

Chronic posterior uveitis is a relatively common clinical disorder and an importance cause of visual impairment in young adults. Experimental autoimmune uveitis (EAU) and its associated experimental autoimmune pinealitis (EAP) induced by retinal autoantigens are predominantly CD4+ T cell mediated (auto) immune disease of the retina and uveal tract of the eye and the pineal gland respectively. EAU bears a close clinical and pathological resemblance to chronic posterior uveitis in humans and seves as a good animal model for the study of posterior uveitis. The EAU model was used to study means of modulating the host's immune response to suppress or inhibit the onset of uveitis. The onset of retinal S-antigen induced EAU could be successfully inhibited by pre-treating Lewis rats with a retinal S-antigen (carboxy terminus) specific monoclonal antibody called S2.4.C5. This however did not suppress the associated EAP indicating that the monoclonal antibody acted via the efferent arc of the immune mediated response. This prompted a study of the 'Blood-retinal and Blood-pineal barrier sites' during the active stages of EAU and EAP. Transmission electron microscopy of the vascular endothelium revealed changes resembling 'High endothelial venules' of lymph nodes in the retinal and pineal vasculature. In an attempt to identify one or more immunodominant epitopes of S-antigen that may be relevant to tolerance induction, an in-vitro and in-vivo study using enzyme digested preparations of S-antigen was carried out. This revealed that digestion of S-antigen by a protease derived from staphylococcus aureus V8 strain, not only inhibited the binding of the monoclonal S2.4.C5 in-vitro but was also associated with an in-vivo attenuation of the pathogenic response to S-antigen indicating that a dominant immunogenic epitope of S-antigen was located at the C-terminus of the molecule.

APA, Harvard, Vancouver, ISO, and other styles

7

Kotaniemi, Kaisu. "Uveitis in juvenile idiopathic arthritis." Helsinki : University of Helsinki, 2002. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/kotaniemi/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kottoor, Sherine Hermangild. "Regulatory T cells in human uveitis." Thesis, University of Birmingham, 2011. http://etheses.bham.ac.uk//id/eprint/3000/.

Full text

Abstract:

Regulatory T cells (Treg) are critical for the maintenance of tolerance to self and control of inflammation. Defects in Treg have been reported for a number of autoimmune and inflammatory diseases. In this thesis I wished to determine whether there are quantitative and/ or qualitative defects of Treg in patients with idiopathic non-infectious uveitis. Using stringent gating procedures, an increased frequency of CD4+CD25highCD127low Treg was observed in the peripheral blood of acute anterior uveitis (AAU) patients but not those with chronic disease. Treg from both acute and chronic anterior uveitis patients expressed defective suppressive capacity in vitro. I also observed an accumulation of memory Treg in the aqueous humor from AAU patients, expressing high levels of FoxP3 and CTLA-4. In vitro activated Treg upregulated their FoxP3 expression to levels as seen in the eye, suggesting that the aqueous humor Treg might be recently activated. Using an in vitro model for analysing Treg function, I observed that exposure to uveitis aqueous humor did not affect the suppressive ability of Treg. In summary, Treg with a potent regulatory phenotype accumulate in the aqueous humor of acute anterior uveitis patients, whereas the peripheral Treg population from both chronic and acute patients express a defective function.

APA, Harvard, Vancouver, ISO, and other styles

9

Chang, John Hyun-Min Medical Sciences Faculty of Medicine UNSW. "Pattern recognition receptors in the immunopathogenesis of acute anterior uveitis." Awarded by:University of New South Wales. School of Medical Sciences, 2006. http://handle.unsw.edu.au/1959.4/25756.

Full text

Abstract:

Acute anterior uveitis (AAU) is the most common form of intraocular inflammatory disease and an important cause of visual impairment. Microbial triggers to the development of AAU have been strongly implicated, however the pathogenesis and molecular mechanisms for this are unclear. Toll-like receptors (TLR) and nucleotide oligomerisation domain receptors (NOD) are pattern recognition receptors (PRR) of the innate immune system that facilitate immediate recognition and immunostimulatory responses to unique molecular patterns of microbial components, including the production of chemoattractant cytokines called chemokines. The major aim of this study was to investigate the role of PRRs, namely TLRs and NODs, in the pathogenesis of human AAU. The mRNA and protein expressions of TLR4 and NOD2 in the normal human eye were determined by RT-PCR and immunohistochemistry. Resident antigen presenting cells of the normal human uvea expressed TLR4 protein. NOD2 protein expression was highly restricted to a subpopulation of retinal cells. A selective perturbation in the expression and function of TLRs were demonstrated in active human AAU by flow cytometry and in vitro stimulation with selective TLR agonists. These changes were not due to any polymorphisms in the TLR genes. Elevated plasma levels of lipopolysaccharide (LPS), an agonist for TLR4, were not detected in patients with active AAU by the limulus amebocyte lysate assay. New information regarding the complex in vivo network of cytokines in active human AAU were provided by multiplex cytokine bead immunoassay on aqueous humor samples, including a Th1-polarised pattern of aqueous humor cytokines, the intraocular expression of multiple LPS-inducible cytokines, and the aqueous humor expression of cytokines such as IL-17 in AAU. Expressions of the respective chemokine receptors on peripheral blood leukocytes were also determined. The findings of this study provides several lines of evidence to support the hypothesis that PRRs, namely TLRs and NODs, are of pathogenic importance in the development of clinical AAU. The results of this study provide significant new information regarding the role of PRRs in ocular immunity and immune privilege, their role in the pathogenesis of AAU, and it provides a molecular mechanism whereby microbial triggers could initiate the development of uveitis.

APA, Harvard, Vancouver, ISO, and other styles

10

Girol, Ana Paula [UNESP]. "Efeito anti-inflamatórios e mecanismo de ação da proteína anexina A1 em modelo de uveíte induzida por endotoxina." Universidade Estadual Paulista (UNESP), 2012. http://hdl.handle.net/11449/102748.

Full text

Abstract:

Made available in DSpace on 2014-06-11T19:32:15Z (GMT). No. of bitstreams: 0 Previous issue date: 2012-10-01Bitstream added on 2014-06-13T19:02:42Z : No. of bitstreams: 1 girol_ap_dr_sjrp.pdf: 2767675 bytes, checksum: affebf6e5d0ac59da5e241e14d9b3745 (MD5)
A proteína anexina A1 (AnxA1) apresenta importantes propriedades anti-inflamatórias e estudos sugerem que suas ações podem ser mediadas por receptores para peptídeos formilados (FPR). Embora os efeitos anti-inflamatórios da AnxA1 e de seus peptídeos miméticos, especialmente o Ac2-26, tenham sido explorados em diversas investigações, são raros os estudos da AnxA1 nas inflamações oculares. Em razão dos graves efeitos colaterais dos tratamentos atuais para a uveíte, uma importante causa de cegueira, investigamos, in vivo, os efeitos e o mecanismo de ação da AnxA1 nos tecidos oculares de roedores na uveíte induzida por endotoxina (EIU). Ratos machos (Rattus novergicus) foram anestesiados e inoculados, por via subcutânea, na pata direita com lipopolissacarídeo (LPS) (100µg) para o desenvolvimento da uveíte. Após, foram divididos em grupos experimentais (n=10/grupo): EIU por 24 e 48h; EIU por 24h e tratados farmacologicamente por administrações tópica e sistêmica do peptídeo Ac2-26 (100µg) e EIU 24h tratado sistemicamente com peptídeo e Boc2, antagonista do FPR (50µg/animal). Para confirmar a importância da AnxA1 endógena na resolução da inflamação ocular, camundongos selvagens e deficientes para AnxA1 (AnxA1-/-) foram induzidos à uveíte por 24h sem tratamento. Nesses animais AnxA1-/- a resposta inflamatória foi exacerbada em comparação com os selvagens. Enquanto, nos olhos dos ratos, as análises quantitativas dos leucócitos, dosagens de interleucina (IL)-1β, IL-6, fator de necrose tumoral (TNF)-α, óxido nítrico (NO) e expressão da ciclo-oxigenase (COX)-2 nos tecidos e/ou no humor aquoso indicaram os efeitos anti-inflamatórios do peptídeo. Efeitos que foram revertidos na presença do Boc2. As análises imuno-histoquímicas das proteínas AnxA1, AnxA1 fosforilada em...
Annexin A1 (AnxA1) is a protein that displays anti-inflammatory properties and some studies suggest that its effects may be mediated by formyl peptide receptors (FPR). Although the anti-inflammatory activities of AnxA1 and its mimetic peptides, including Ac2-26, have been explored in several investigations, the role of AnxA1 in ocular inflammatory processes has not yet been elucidated. Given the common side effects of the current therapies used to treat uveitis, an important cause of blindness worldwide, we investigated, in vivo, the AnxA1 effects and mechanism of action in endotoxin-induced uveitis (EIU). Rattus norvegicus were induced to uveitis (lipopolysaccharide - 100 µg) and divided into experimental groups (n=10/group): EIU untreated for 24 and 48h, EIU treated with topical applications (4/4h) or a single intravenous injection of Ac2-26 (100µg) and EIU systemically treated with the peptide and Boc2, the FPR antagonist (50µg/animal). To confirm the importance of endogenous AnxA1 in the resolution of ocular inflammation, wild-type and AnxA1 deficient (AnxA1-/-) mice were also induced to uveitis without treatment for 24h. AnxA1-/- mice showed exacerbated inflammation compared to wild-type animals. As, quantitative analyses of leukocytes, interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, nitric oxide (NO) levels and cyclooxigenase (COX)-2 expression in ocular tissues and/or in aqueous humor of rats eyes revealed the anti-inflammatory effects of the peptide, which were abrogated in the Boc2 presence. Immunohistochemical analysis of AnxA1, serine-or-tyrosine-phosphorylated AnxA1 (AnxA-S27-PO4 - AnxA-Y21-PO4) in the ocular tissues showed AnxA1 and AnxA1-S27-PO4 expression in epithelial (cornea, iris and ciliary processes) and nervous cells. These expressions were increased in... (Complete abstract click electronic access below)

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Uveitis"

1

Foster, C. Stephen, Stephen D. Anesi, and Peter Y. Chang, eds. Uveitis. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-52974-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lin, Phoebe, ed. Uveitis. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-0331-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Papaliodis, George N., ed. Uveitis. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-09126-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Opremcak, E. Mitchel. Uveitis. New York, NY: Springer New York, 1995. http://dx.doi.org/10.1007/978-1-4612-4174-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Smith, Ronald E., Robert A. Nozik, and Günther Grabner. Uveitis. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70809-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lightman, Susan. Uveitis. London: BMJ Books, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gilbert, Smolin, and Friedlaender Mitchell H, eds. Uveitis. Boston: Little, Brown, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rao, Narsing A., Julie Schallhorn, and Damien C. Rodger, eds. Posterior Uveitis. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03140-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

F, Tabbara Khalid, ed. Posterior uveitis. Boston, Mass: Little, Brown, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

W, Böke, Manthey K. F, Nussenblatt Robert B, and Bertelsmann Stiftung (Gütersloh Germany), eds. Intermediate uveitis. Basel: Karger, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Uveitis"

1

Foster, C. Stephen. "Uveitis." In Risk Prevention in Ophthalmology, 237–45. New York, NY: Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-73341-8_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ebrahimiadib, Nazanin, Fedra Hajizadeh, and Marjan Imani Fooladi. "Uveitis." In Diagnostics in Ocular Imaging, 517–33. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-54863-6_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Yoshimura, Nagahisa, and Masanori Hangai. "Uveitis." In OCT Atlas, 277–301. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-38625-1_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Augustin, Albert J. "Uveitis." In Augenheilkunde, 263–89. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-662-05919-7_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Collins, James F., and Albert J. Augustin. "Uveitis." In Augenheilkunde, 231–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-662-05922-7_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lee, Joan. "Uveitis." In Optical Coherence Tomography, 97–109. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-24817-2_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Fagan, Xavier, Weng Onn Chan, Lyndell Lim, and Jagjit S. Gilhotra. "Uveitis." In Spectral Domain Optical Coherence Tomography in Macular Diseases, 353–80. New Delhi: Springer India, 2016. http://dx.doi.org/10.1007/978-81-322-3610-8_25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Walton, R. Christopher. "Uveitis." In Ophthalmology in Military and Civilian Casualty Care, 135–46. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-14437-1_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Samson, Anda. "Uveitis." In Practical Clinical Microbiology and Infectious Diseases, 354–56. First edition. | Boca Raton : CRC Press, 2020.: CRC Press, 2020. http://dx.doi.org/10.1201/9781315194080-4-63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Khalil, Mostafa, Omar Kouli, and Obaid Kousha. "Uveitis." In The Duke Elder Exam of Ophthalmology, 133–44. Boca Raton : Taylor & Francis, 2020.: CRC Press, 2019. http://dx.doi.org/10.1201/9780429275081-13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Uveitis"

1

Della, Felipe Cargnelutti Possamai, Mônica Ribeiro de Campos, Suelem Estefano Ramos, Camila Lucía Veroneze Solórzano, Vanessa de Quadros Martins, Jean Paulo Veronese de Souza, Deise Marcela Piovesan, Bárbara Mendes da Silva, Iloite Maria Scheibel, and Markus Markus Bredemeier. "TUBULOINTERSTITIAL NEPHRITIS AND UVEITIS." In XXXIX Congresso Brasileiro de Reumatologia. Sociedade Brasileiro de Reumatologia, 2022. http://dx.doi.org/10.47660/cbr.2022.2122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

CRACCO, LUIZ AUGUSTO FANHANI, Fabio Henrique Carneiro, André Wilson de Lima Oliveira, Afonso Gomes de Oliveira, Gustavo Koíti Kondo, Marian Hanae Oda, Marina Machado Pereira, Roberta Zawadzki Bueno, Chayanne Natielle Rossetto, and Eduardo S. Paiva. "Takayasu’s arteritis with uveitis." In XXXIX Congresso Brasileiro de Reumatologia. Sociedade Brasileiro de Reumatologia, 2022. http://dx.doi.org/10.47660/cbr.2022.1934.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

GARCíA, JAVIER, and Eugenio Perez-Blazquez. "FRI0590 UVEITIS SECONDARY TO CHECKPOINT INHIBITORS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.5473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sotnikova, L. F., A. V. Goncharova, S. F. Nazimkina, and A. F. Baranova. "Ecological problems in itheology of uveitis." In PROCEEDINGS OF THE II INTERNATIONAL CONFERENCE ON ADVANCES IN MATERIALS, SYSTEMS AND TECHNOLOGIES: (CAMSTech-II 2021). AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0095849.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Konovalova, N. V., and N. I. Khramenko. "To the Treatment of Anterior Uveitis." In 2019 IEEE 8th International Conference on Advanced Optoelectronics and Lasers (CAOL). IEEE, 2019. http://dx.doi.org/10.1109/caol46282.2019.9019547.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

GARCIA, LEANDRO DINIZ, PALOMA LILIAN ANDRADE PEDROSO, BIANCA RODRIGUES MOTA, ANNA CLARA FACHETTI CARVALHO, CLARA MONTEIRO REIS, and RODOLFO PEREIRA ESPÍNDOLA. "CHRONIC UVEITIS ASSOCIATED WITH PULMONARY TUBERCULOSIS." In 36º Congresso Brasileiro de Reumatologia. São Paulo: Editora Blucher, 2019. http://dx.doi.org/10.5151/sbr2019-054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kretova, Elizaveta, Asrath Rahman, Daiana Bassi, Yun Fu, Dean Mohamedally, Gemma Molyneux, Graham Roberts, Neil J. Sebire, Jugnoo Rahi, and Ameenat Lola Solebo. "21 Development of a digital self-care management application for children with Uveitis: Uveitis Patient Passport." In GOSH Conference 2020 – Our People, Our Patients, Our Hospital. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2020. http://dx.doi.org/10.1136/archdischild-2020-gosh.21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gentil, M., K. Racz, J. C. Eule, and E. Müller. "Infektionserreger im Kammerwasser von Pferden mit Uveitis." In 28. Jahrestagung der FG „Innere Medizin und klinische Labordiagnostik“ der DVG (InnLab) – Teil 2: Poster. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-1700927.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Yasar Bilge, Nazife Sule, Timuçin Kaşifoğlu, Sedat Kiraz, Ali İhsan Ertenli, Orhan Küçükşahin, Ediz Dalkılıç, Cemal Bes, et al. "THU0410 UVEITIS RELATED FACTORS IN PATIENTS WITH SPONDYLOARTHRITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.6147.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Sampaio, Romão Augusto Alves Filgueira, Mailze Campos Bezerra, and Leonardo Ribeiro Sampaio. "TUBERCULAR UVEITIS IN A PATIENT WITH RHEUMATOID ARTHRITIS." In XXXIX Congresso Brasileiro de Reumatologia. Sociedade Brasileiro de Reumatologia, 2022. http://dx.doi.org/10.47660/cbr.2022.1781.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Uveitis"

1

Li, Biao, Haoran Li, Li Zhang, and Yanlin Zheng. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2020. http://dx.doi.org/10.37766/inplasy2020.10.0116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Li, Biao, Haoran Li, Li Zhang, and Yanlin Zheng. Efﬁcacy and safety of adalimumab in the treatment of Juvenile Idiopathic Arthritis-Associated Uveitis: a meta-analysis and systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!